ArticleIndian journal of ophthalmology2026
Mortality in neovascular glaucoma.
Article in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo characterize the impact of neovascular glaucoma (NVG) and its underlying etiology on mortality and determine the association between NVG and cause of death.
designRetrospective cohort study.
participantsA total of 210 subjects with NVG were included in the descriptive study. Of the 210 subjects, 132 with a definite date of NVG onset were included in the survival analysis.
methodsPatients with NVG seen at our tertiary care center from 2015-2016 were identified. Demographic information, underlying etiology, and medical conditions were documented. The Centers for Disease Control and Prevention National Death Index (CDC NDI) was used to designate if subjects were alive on December 31, 2021, and to determine the primary cause of death. Kaplan-Meier and Cox proportional hazard regression analyses were performed on subjects with a definitive date of NVG onset.
resultsOf the 210 subjects, 32% were deceased by December 31, 2021. The commonest diagnosis was proliferative diabetic retinopathy (PDR) (57%), followed by central retinal vein occlusion (CRVO) (29%). Of 132 subjects included in the Kaplan-Meier survival analysis, the mean survival time was 154 ± 15 months (95% CI: 125-183). Cox regression analysis demonstrated that older age (HR 1.03, 95% CI: 1.004-1.06, P = 0.02) and central retinal artery occlusion (CRAO) (HR: 4.63, 95% CI: 1.7-12.44, P = 0.002) were associated with poorer survival.
conclusionsIncreasing age and CRAO-related NVG (compared to CRVO-unrelated) were important predictors of increased mortality. Our results highlight the need for aggressive management of underlying systemic co-morbid conditions contributing to early mortality in patients with NVG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.